Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Insulin Efsitora Alfa→

Insulin Efsitora Alfa PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2131038-11-2
Molecular formula
C2810H4296N776O882S32
Molecular weight
64090 g/mol
Drug class
Long-acting basal insulin analogueantidiabetic hormone
Mechanism of action
Activates insulin receptors to regulate glucose metabolism, increasing peripheral glucose uptake (especially in skeletal muscle and adipose tissue) and suppressing hepatic glucose production. Its prolonged weekly action reflects reduced renal clearance, FcRn binding and reduced insulin-receptor affinity relative to human insulin.
Indications / reported uses
  • Improvement of glycaemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise, under the current product label.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e02229e-262c-4e25-9240-9e9de4eb7c1d · https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-once-weekly-insulin-type-2-diabetes-mellitus · https://www.ema.europa.eu/en/medicines/human/EPAR/onswik

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Long-acting basal insulin analogue; antidiabetic hormone

Mechanism of action

Activates insulin receptors to regulate glucose metabolism, increasing peripheral glucose uptake (especially in skeletal muscle and adipose tissue) and suppressing hepatic glucose production. Its prolonged weekly action reflects reduced renal clearance, FcRn binding and reduced insulin-receptor affinity relative to human insulin.

General use cases

  • Improvement of glycaemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise, under the current product label.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Insulin Efsitora Alfa PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Insulin Efsitora Alfa Permitted Daily Exposure (PDE) report (the Insulin Efsitora Alfa PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Insulin Efsitora Alfa Occupational Exposure Limit (OEL) report (the Insulin Efsitora Alfa OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.